Gilead Sciences (GILD): Bright Spots Among The Misses - Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Bullish Options Activity in Gilead Sciences (GILD) Post Earnings Announcement -Susquehanna
May 3, 2017 2:46 PM EDTSusquehanna options strategists Alison Edwards notes bullish options activity in Gilead Sciences (NASDAQ: GILD), following the company's earnings announcement, as an opening investor bought ~10,000 Dec 70 Calls for $3.30 creating ~400,000 shares to buy.
... MoreGilead Sciences (GILD) PT Raised to $76 at BMO Capital Following 1Q
May 3, 2017 9:17 AM EDTBMO Capital raised its price target on Gilead Sciences (NASDAQ: GILD) to $76.00 (from $75.00) while maintaining a Market Perform rating. GILD reported 1Q revenues of $6.5bn, below the Street's estimates of $6.62bn, as continued strength from HIV could not off-set further deterioration in HCV.
GILD... More
